A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus
Arthritis Rheumatol. 2022 Oct 17. doi: 10.1002/art.42389. Online ahead of print.
ABSTRACT
OBJECTIVE: Systemic lupus erythematosus (SLE) is marked by immune dysregulation linked to varied clinical disease activity. Using a unique longitudinal cohort of SLE patients, this study sought to identify optimal immune mediators informing an empirically refined flare risk index (FRI) reflecting altered immunity prior to clinical disease flare.